Financial Performance Highlights
Q2 FY27 vs Q2 FY26 (YoY Comparison):
- Revenue from operations: INR 288.4 crore (vs INR 230.4 crore) - 25.2% increase
- EBITDA: INR 49.7 crore (vs INR 37.9 crore) - 31.1% increase
- EBITDA margin: 17.23% (vs 16.45%)
- Profit before tax: INR 31.5 crore (vs INR 20.5 crore) - 53.7% increase
- PBT margin: 10.95% (vs 8.89%)
- Profit after tax: INR 23.5 crore (vs INR 14.9 crore) - 57.7% increase
- PAT margin: 8.15% (vs 6.47%)
H1 FY27 vs H1 FY26 (Half-yearly Comparison):
- Revenue from operations: INR 549.2 crore (vs INR 457.3 crore) - 20.1% increase
- EBITDA: INR 96.9 crore (vs INR 71.1 crore) - 36.3% increase
- EBITDA margin: 17.64% (vs 15.55%)
- Profit before tax: INR 61.7 crore (vs INR 36.8 crore) - 67.7% increase
- Profit after tax: INR 46.0 crore (vs INR 27.0 crore) - 70.4% increase
- PAT margin: 8.38% (vs 5.90%)
Regulatory Updates - Indore Plant
- US FDA completed pre-approval inspection with 3 observations (non-critical) - team addressing within stipulated timeframe
- EU GMP compliance report submitted - awaiting certification
- Hosted audits from prospective US and UK market partners
- Plant registered with US FDA and first product dossier filed
- Targeting US market entry by Q2/Q3 2028 and Europe entry by September 2027
Business Segment Performance
International Business:
- Received 3 registrations in Saudi Arabia with first orders
- First commercial order in Chile through partner
- First order for antifungals in UK and Germany
- Entered Italy through partner and extended distribution to 5 European countries via Gufic Ireland
- Targeting 156-182 marketing authorizations across 22-24 countries
Domestic Business - Hospital Injectables:
- AWABAC (launched June) established across corporate, tertiary, and secondary care hospitals
- Anti-infective franchise continued growth with improved position in key antifungal classes
- Sparsh division: company-manufactured brands now majority of business
- Dual-chamber bag gaining acceptance at leading institutions
- Pilot program for smaller nursing homes in Mumbai initiated
Women's Health:
- Ferticare leading in recurrent implantation failure with Guficin Alpha
- Research article published and clinical practice recommendations released
- Puregraf group deepened presence in corporate IVF chains
- Cetrocare introduced in prefilled syringe format
Aesthetics & Therapeutics:
- Stunnox (botulinum toxin) completed 5 years in market - second-largest brand in segment
- Consensus recommendation on dosing in Indian patients published
- Three clinical studies initiated
- Dermal filler range from Canadian partners in preparation
- NeuroCare growing in core indications and extending to adjacent specialties
Healthcare Division:
- Sallaki range continued growth - leadership in Boswellia serrata segment
- Gufican Oil fastest-growing brand in division
- Napro Pure launched - first step into allopathic pain management
Operational Updates
- Depot suite ready for trials and media fills
- Spray-dried route for lipid-based antifungal near completion
- Injectable emulsion format moved through scaleup
- Output across all four production lines higher than Q1
- R&D focus on peptides, API self-reliance, and novel drug delivery systems
- 17 active and pipeline clinical studies ongoing
Financial Position & Guidance
- Gross margin dipped due to rupee devaluation affecting API import prices and increased transportation costs
- Inventory increased to INR 370 crore (from normal ~INR 325-330 crore) due to geopolitical concerns and validation batches for regulated markets
- Debt increased due to working capital requirements and inventory buildup
- Capex of INR 20-30 crore annually financed through internal accruals
- Semaglutide investment of INR 22-25 crore expected to yield returns from Q1/Q2 next year
- Target: 15-20% annual revenue growth
- EBITDA margin target: 22-25% over medium term with 1% annual improvement
Management Commentary
- Indore plant currently at EBITDA breakeven, expected to cover depreciation and interest by Q4 FY27
- International revenue mix: 65-70% from regulated markets (Europe, South Africa, Brazil, Colombia, UK)
- Botulinum toxin revenue: ~$3.5-3.6 million annually, targeting 25-30% growth
- Domestic business growth: ~12% annually
- International business growth: ~20-22% annually
- CMO business growth: ~4-5% annually
Future Outlook
- Expect margin normalization by Q4 FY27
- Planning 4-6 additional molecules at Indore between November 2026-March 2027
- Targeting 10-15% market share in addressable market of INR 824 million across 22-24 countries
- Next phase of international investment to focus on botulinum toxin, depot, and liposomal products
- Continuing evolution into complex products including once-in-a-week antibiotics, depots, liposomal products, and recombinant molecules